Connection

Laurent Peyrin-Biroulet to Drug Administration Schedule

Back to Details
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Drug Administration Schedule.
Laurent Peyrin-Biroulet
Connection Strength
0.188
Drug Administration Schedule
  1. Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational study. Dig Liver Dis. 2019 02; 51(2):236-241.
    View in: PubMed
    Score: 0.112
  2. Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):597-606.
    View in: PubMed
    Score: 0.025
  3. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017 07; 46(2):142-149.
    View in: PubMed
    Score: 0.025
  4. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut. 2018 01; 67(1):53-60.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.